Hemp plants contain dozens of bioactive cannabinoid molecules and one of them, CBG, is starting to edge onto the main stage with its better known peer, CBD.
Canada-based Willow Biosciences Inc. has announced it will soon start to deliver its first samples of “ultra-pure, pharmaceutical grade” cannabigerol (CBG) from its 500-liter pilot production run.
Colorado-based Geocann has launched two CBG (cannabigerol) formulations, optimizing absorption and bioavailability by utilizing the VESIsorb drug delivery system.